Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Xiaoer Lianhua Qinggan Granule in children with acute upper respiratory tract infection
ChiCTR2300073643Phase 3Recruiting
- Sponsor
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of xiaoer lianhua qinggan granule in upper respiratory infection (URI) (2 arms), sponsored by First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoint: Clinical cure rate of the disease. Started Feb 2023; status: recruiting.
02
Drugs
xiaoer lianhua qinggan granule
03
Conditions
upper respiratory infection (URI)
Beyond the preview
Go deeper on ChiCTR2300073643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073643.